Emergence of linezolid- and vancomycin-resistant Enterococcus faecium in a department for hematologic stem cell transplantation.

Background

Data from 2014 of the European Antimicrobial Resistance Surveillance Network (EARS-Net) reported the proportion of vancomycin resistance in Enterococcus faecium in Europe being 8.9 % [ 1 ]. The VRE rate in Germany has increased dramatically in the last years [ 2 ]: Between 2007 and 2012 surgical site and bloodstream infections due to VRE increased significantly (526 and 278 %) [ 2 ].

Infections with VRE are a major cause of morbidity in HSCT recipients [ 3 ]. Universal use of central venous catheters, heavy exposure to prophylactic and therapeutic anti-infectives, numerous periods of hospitalization and extensive contact to health-care providers predisposes this patient cohort to colonization and subsequent infections with resistant pathogens such as VRE [ 4 ].

Linezolid resistance in VRE (LVRE) is an uncommon finding. Case reports and outbreaks of LVRE have been described from US, Greece, Italy and Ireland mainly in intensive care unit patients, patients after solid organ transplantation or with hematological malignancy [ 5 – 10 ]. Linezolid exposure and patient-to-patient transmission were shown to be main factors for LVRE infection [ 11 ].

In this retrospective study (2014–2015) cases with LVRE in a university-based HSCT department were reviewed to understand the epidemiology. In addition, LVRE isolates were characterized and genotyped to assess possible strain transmission between patients.

Methods

Setting and patient population

The epidemiology of linezolid resistance in VRE was investigated in the department for HSCT belonging to the West German Cancer Center within the University Hospital Essen over a period of 2 years (2014–2015). The HSCT department provides specialist superregional services for adult patients with hematological malignancies. In 2014 and 2015 394 patients underwent allogeneic HSCT. The clinic consists of three spatially separated wards. The VRE rate (one isolate per patient) was in 2014 9.6 % and in 2015 15 %. All patients positive for LVRE and with a stay in the HSCT department in the year 2014 and 2015 were included in the study. Patient chart review was performed to retrieve clinical information from the patients with LVRE.

Infection control measures

All incoming patients were screened for VRE by obtaining rectal swabs or stool samples in outpatient facilities before admission to the HSCT department. From every hospitalized HSCT patient, surveillance cultures (rectal swab/stool sample, urine, blood, respiratory secretions) were weekly obtained. Infection control measures were performed according to guidelines for preventing infectious complications among hematopoietic cell transplant recipients: All patients were placed in single-patient rooms. The rooms are protective environment rooms consisting with high efficiency particulate air filter (HEPA). Standard precautions include hand hygiene and wearing personal protective equipment (gown, cap and gloves) were recommended for hospital staff and visitors before entering the room [ 12 ]. Environmental samples from patient’s rooms (sink, shower etc.) were investigated on a regular basis (every 4 weeks in each patient’s room) for bacterial and fungal contamination. The swabs were cultured on standard media (blood agar, MacConkey agar, chromogenic Candida agar).

Bacterial isolation, identification and antibiotic-susceptibility testing

Chromogenic medium (VRESelect, Bio-Rad, Munich, Germany) selective for VRE was used for all rectal and stool screening samples. Species identification was performed by using MALDI-TOF mass spectrometry (VITEK MS, bioMérieux, Nürtingen, Germany). Susceptibility testing was conducted using the VITEK 2 system (bioMérieux) and interpretation of clinical MIC breakpoints was performed according to EUCAST. The MIC breakpoint of linezolid according to EUCAST is > 4 μg/mL . For daptomycin the breakpoint (>4 μg/ml) was used from CLSI. All isolates with resistance against linezolid were confirmed by linezolid MIC test strip (Liofilchem, Roseto degli Abruzzi, Italy). Saved isolates were stored at −80 °C until further characterization.

In total, nine isolates were available for further analyses at the German Reference Center for Staphylococci and Enterococci (Robert Koch Institute, Wernigerode, Germany). There, antibiotic susceptibility testing was performed by broth microdilution (BMD) as previously described [ 13 ].

Determination of van, virulence and cfr genes

PCR analysis for glycopeptide resistance genes ( vanA and vanB ) and virulence markers ( esp , hyl ) was performed using standard protocols [ 14 ]. Part of the cfr gene was amplified as previously described [ 15 ]. Nucleotide changes in 23S rDNA conferring linezolid resistance were determined and calculated using a previously described assay. It is a combination of a PCR amplification of the six 23S rDNA alleles in E. faecium followed by a restriction digestion recognizing the mutated nucleotide position and a subsequent gelchip-based separation of the digested vs. non-digested fragments allowing a quantification [ 16 ].

Macrorestriction analysis

Macrorestriction analysis for the LVRE isolates were performed using the restriction endonuclease Sma I with subsequent PFGE as reported [ 13 ].

Statistics

Graphics were generated with GraphPad Prism (La Jolla, USA).

Results

Characteristics of LVRE patients

In the observed time period, 20 patients were found to be colonized or infected with LVRE in the HSCT department. The percentage of LVRE among VRE in the HSCT department was 27 % in 2014 and 20 % in 2015. All patient characteristics are shown in Table 1 . Eighteen of these 20 patients underwent HSCT; the two remaining patients had a hematological malignancy with prolonged neutropenia. In five cases (25 %) a bloodstream infection with LVRE occurred. In two of the five cases (40 %) the LVRE bacteremia was associated with death of the patient. In the other 15 cases, LVRE was predominantly found in the gut (positive stool or rectal swab) or in the urinary tract. Overall, eight patients died on the HSCT ward or were discharged into palliative care (40 %). Table 1 Clinical characteristics of 20 patients with linezolid- and vancomycin-resistant Enterococcus faecium (LVRE) and phenotypic and genotypic features of nine further characterized LVRE isolates Patient no. Sex (age [yr]) Underlying Disease Allogeneic HSCT Localisation of LVRE (except bloodstream) Bloodstream infection with LVRE Previous linezolid exoposure Clinical outcome Previous hospital MICs (mg/L) of the nine further characterized LVRE isolate PFGE type Linezolid Vancomycin Teicoplanin Daptomycin 1 M (66) lymphoma yes rectal no yes death A – – – – – 2 M (64) arthritis-metothrexat no urine no yes discharge unknown – – – – – 3 F (34) acute myeloic leukemia yes rectal, inguinal yes yes death C – – – – – 4 F (47) acute myeloic leukemia yes rectal, urine no unknwon discharge D – – – – – 5 M (70) acute myeloic leukemia yes rectal yes yes discharge E – – – – – 6 F (54) acute myeloic leukemia yes rectal, oral cavity, BAL no unknown death D – – – – – 7 F (48) myelodysplastic syndrome yes rectal, inguinal, wound yes yes death C 16 512 64 2 II 8 F (67) acute lymphatic leukemia yes anal, inguinal, oral cavity yes unknown discharge in palliative care D – – – – – 9 F (70) myelodysplastic syndrome yes rectal, armpit, urine no yes discharge D >32 512 128 2 I 10 F (68) aplastic anemia yes urine no unknown death D – – – – – 11 F (20) acute myeloic leukemia yes urine no unknown discharge D – – – – – 12 M (58) myelodysplastic syndrome yes rectal, inguinal no unknown discharge D 32 512 128 2 I 13 F (58) acute myeloic leukemia yes rectal, urine no unknown discharge D 16 512 128 2 I 14 M (53) acute myeloic leukemia yes rectal, hair yes no discharge D 16 512 128 4 I 15 F (10) histiocytosis yes rectal, urine no unknown discharge F – – – – – 16 F (22) acute myeloic leukemia yes rectal no no discharge D 16 512 128 2 I 17 M (62) acute myeloic leukemia yes rectal, oral cavity no unknown discharge D 16 512 128 2 I 18 M (57) acute myeloic leukemia yes rectal, urine no unknown death D – – – – – 19 F (70) acute myeloic leukemia yes rectal, oral cavity, urine no yes discharge G 32 512 128 2 IV 20 M (54) multiple myeloma no rectal no yes Discharge in palliative care H 16 1024 <1 2 III Abbreviations : MIC minimum inhibitory concentration, PFGE pulsed-field gel electrophoresis

Epidemiological investigations

Chart review revealed that all three spatially separated wards were affected (Fig. 1 ). All LVRE patients stayed in different patient rooms. Results from routine microbiological surveillance swabs from the patient-near environment exhibit no LVRE (data not shown). Fig. 1 Epidemiological map of 20 patients with LVRE on three wards in the department of hematologic stem cell transplantation. For patient number 6 the first detection of LVRE was already at the end of 2013. A stay in ambulance is only presented, if there was a detection of LVRE

In 10 of 20 patients LVRE was found before or at date of admission in the HSCT department. By analysis of the hospitals from which the patients were referred, 12 of 20 patients were previously treated in hospital D (Table 1 ). Based on the epidemiological analysis there was no evidence for LVRE transmissions within the HSCT department (Fig. 1 ). Pretreatment with linezolid before LVRE detection could only be demonstrated for the patients with LVRE acquisition during the hospital stay. Eight of 10 patients had prior linezolid therapy before LVRE detection (Table 1 ).

Antimicrobial susceptibility profiles and molecular characterization of LVRE

All 20 LVRE isolates had MICs for linezolid of ≥ 16 mg/L. The in vitro activity using BMD method for linezolid, vancomycin, teicoplanin and daptomycin against the nine saved LVRE isolates are shown in Table 1 . All tested isolates were positive for esp and two for hyl . Eight LVRE carried vanA , one isolate vanB (patient number 20). PCR for cfr gene was negative for all isolates. The most frequent resistance mechanism in Enterococcus is a nucleotide change at position 2576 (G2576U) in the central region of domain V of 23S rRNA. All nine linezolid-resistant isolates possessed a combination of wildtype and mutated allele variants typical for clinical enterococcal isolates showing linezolid resistance.

PFGE typing

PFGE analysis of 9 LVRE isolates showed in total four unrelated genotypes. In six isolates, one single clone could be detected. These isolates belong to patients that were treated in hospital D before admission to the HSCT department. The three other LVRE were not closely genetically related.

Discussion

To the best of our knowledge, this report constitutes the first description of a cluster of LVRE in HSCT recipients and shows also the first epidemiological data from Germany.

One study reported that immunodeficiency, hematological malignancy, hospitalization in a hematological ward and prolonged antibiotic treatment have been identified as risk factors for the development of linezolid resistance in enterococci [ 7 ]. Furthermore, pre-treatment with linezolid was shown to select for LVRE [ 17 ]. However, LVRE can also be found in patients without previous linezolid therapy [ 18 ].

LVRE infections are a serious therapeutic challenge as alternative antimicrobial agents are strongly limited. Twenty-five percent of HSCT recipients had LVRE bacteremia and 40 % of these were associated with fatal outcome. Daptomycin as a new last resort antibiotic can be in these cases one feasible option. According to the MIC-breakpoint of CLSI for daptomycin (≤4 mg/L) all nine LVRE isolates were susceptible to this antibiotic. It was recently reported that Enterococcus faecium bacteremia with increased daptomycin MICs (3–4 μg/mL) was shown to be associated with predicted microbiological failure of daptomycin therapy [ 19 ]. One of the isolates had a daptomycin MIC of 4 mg/L.

The majority of our HSCT patients had multiple risk factors for colonization and/or infection with (L)VRE. Based on the epidemiological analyses and the VRE screening results at admission we found that 60 % of LVRE patients were referred from one specific hospital (D) from which two-thirds had LVRE at the date of admission to the HSCT unit. Furthermore, the typing analyses showed that six of the nine saved LVRE isolates were clonally related. The patients with these clones were all pretreated in hospital D indicating that this clonal cluster was brought into the HSCT department from an external source.

In contrast, the identification of three other unrelated LVRE genotypes from different patients underscores that the cluster of LVRE was not only due to this “local outbreak in hospital D” but was rather a multifactorial event of LVRE emergence in a high-risk patient collective. On the one hand, LVRE emerged due to linezolid therapy which received 8 of 10 patients without LVRE at admission. On the other hand, there were also independent events of de novo selection of linezolid-resistant mutants in VRE-positive patients.

Even though, the HSCT department was heavily affected with LVRE patients we found no hints for transmission between patients or from the environment to the patients. The surveillance screening of all incoming patients for (L)VRE for the early detection and prompt initiation of hygienic barrier measures for all affected patients may be the reason why there is no proof for LVRE patient-to-patient transmission within the HSCT department. Our study has some limitations. Firstly, it was not possible to save all LVRE isolates of the affected patients. Thus, the expressiveness concerning the clonal spread is limited. Secondly, due to the retrospective study design we were not able to give enough evidence for certain risk factors for LVRE colonization/infection or treatment outcome in our HSCT recipients. Also, this is a case only study that has no comparison group. Further studies to identify risk factors and to determine optimal treatment in this predisposed high-risk patient collective are warranted.

Conclusions

In conclusion, LVRE emerged in HSCT recipients in a German university hospital. Our study indicates that (L)VRE screening at patients’ admission and appropriate infection control strategies were sufficient to prevent any intra-department transmissions.

Abbreviations

Hematologic stem cell transplantation

Linezolid- and vancomycin-resistant enterococci

Pulsed-field gel electrophoresis

Vancomycin-resistant enterococci

Acknowledgment

Not applicable.

Funding

This study was supported by internal funding of the University of Essen.

Availability of data and materials

All data generated or analysed during this study are included in this published article.

Authors’ contributions

MK collected and analysed the epidemiological data. IK performed the PFGE typing. BR, RT, DB, JB, PR, JS received and designed the study. MK, BR, JS, PR, JB DB, RT interpreted the data. MK, DT, ES, JS wrote the manuscript. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Not applicable.

Ethics approval and consent to participate

The study was reviewed and approved by the University Hospital Essen Review Board (number 15-6732-BO).

References

1. EARS-Net. European Antimicrobial Resistance Surveillance Network (EARS-Net). http://ecdc.europa.eu/en/activities/surveillance/EARS-Net/Pages/index.aspx [accessed 26 January 2016].

2. Gastmeier P Schroder C Behnke M Meyer E Geffers C Dramatic increase in vancomycin-resistant enterococci in Germany J Antimicrob Chemother 2014 69 1660 1664 10.1093/jac/dku035 24615816

3. Vydra J Shanley RM George I Ustun C Smith AR Weisdorf DJ Enterococcal bacteremia is associated with increased risk of mortality in recipients of allogeneic hematopoietic stem cell transplantation Clin Infect Dis 2012 55 764 770 10.1093/cid/cis550 22693346 PMC3657510

4. Salgado CD Ison MG Should clinicians worry about vancomycin-resistant Enterococcus bloodstream infections? Bone Marrow Transplant 2006 38 771 774 10.1038/sj.bmt.1705532 17133239

5. O’Driscoll C Murphy V Doyle O Wrenn C Flynn A O’Flaherty N First outbreak of linezolid-resistant vancomycin-resistant Enterococcus faecium in an Irish hospital, February to September 2014 J Hosp Infect 2015 91 367 370 10.1016/j.jhin.2015.09.006 26520594

6. Ntokou E Stathopoulos C Kristo I Dimitroulia E Labrou M Vasdek A Intensive care unit dissemination of multiple clones of linezolid-resistant Enterococcus faecalis and Enterococcus faecium J Antimicrob Chemother 2012 67 1819 1823 10.1093/jac/dks146 22532462

7. Souli M Sakka V Galani I Antoniadou A Galani L Siafakas N Colonisation with vancomycin- and linezolid-resistant Enterococcus faecium in a university hospital: molecular epidemiology and risk factor analysis Int J Antimicrob Agents 2009 33 137 142 10.1016/j.ijantimicag.2008.08.017 19013056

8. Gonzales RD Schreckenberger PC Graham MB Kelkar S Denbesten K Quinn JP Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid Lancet 2001 357 1179 10.1016/S0140-6736(00)04376-2 11323048

9. Bonora MG Solbiati M Stepan E Zorzi A Luzzani A Catania Fontana R Emergence of linezolid resistance in the vancomycin-resistant Enterococcus faecium multilocus sequence typing C1 epidemic lineage J Clin Microbiol 2006 44 1153 1155 10.1128/JCM.44.3.1153-1155.2006 16517918 PMC1393143

10. Ryan L O’Mahony E Wrenn C Fitzgerald S Fox U Boyle B Epidemiology and molecular typing of VRE bloodstream isolates in an Irish tertiary care hospital J Antimicrob Chemother 2015 70 2718 2724 10.1093/jac/dkv185 26142479

11. Kainer MA Devasia RA Jones TF Simmons BP Melton K Chow S Response to emerging infection leading to outbreak of linezolid-resistant enterococci Emerg Infect Dis 2007 13 1024 1030 10.3201/eid1307.070019 18214174 PMC2878236

12. Tomblyn M Chiller T Einsele H Gress R Sepkowitz K Storek J Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective. Preface Bone Marrow Transplant 2009 44 8 453 455 10.1038/bmt.2009.254 19861977

13. Werner G Fleige C Neumann B Bender JK Layer F Klare I Evaluation of DiversiLab (R), MLST and PFGE typing for discriminating clinical Enterococcus faecium isolates J Microbiol Methods 2015 118 81 84 10.1016/j.mimet.2015.08.019 26341611

14. Werner G Fleige C Ewert B Laverde-Gomez JA Klare I Witte W High-level ciprofloxacin resistance among hospital-adapted Enterococcus faecium (CC17) Int J Antimicrob Agents 2010 35 119 125 10.1016/j.ijantimicag.2009.10.012 20006472

15. Kehrenberg C Schwarz S Distribution of florfenicol resistance genes fexA and cfr among chloramphenicol-resistant Staphylococcus isolates Antimicrob Agents Chemother 2006 50 1156 1163 10.1128/AAC.50.4.1156-1163.2006 16569824 PMC1426988

16. Klare I Fleige C Geringer U Thürmer A Bender J Mutters NT Increased frequency of linezolid resistance among clinical Enterococcus faecium isolates from German hospital patients J Glob Antimicrob Resistance 2015 3 2 128 131 10.1016/j.jgar.2015.02.007 27873661

17. Scheetz MH Knechtel SA Malczynski M Postelnick MJ Qi C Increasing incidence of linezolid-intermediate or -resistant, vancomycin-resistant Enterococcus faecium strains parallels increasing linezolid consumption Antimicrob Agents Chemother 2008 52 2256 2259 10.1128/AAC.00070-08 18391028 PMC2415807

18. Rahim S Pillai SK Gold HS Venkataraman L Inglima K Press RA Linezolid-resistant, vancomycin-resistant Enterococcus faecium infection in patients without prior exposure to linezolid Clin Infect Dis 2003 36 E146 E148 10.1086/374929 12766857

19. Shukla BS Shelburne S Reyes K Kamboj M Lewis JD Rincon SL Influence of Minimum Inhibitory Concentration in Clinical Outcomes of Enterococcus faecium Bacteremia Treated With Daptomycin: Is it Time to Change the Breakpoint? Clin Inf Dis 2016 62 12 1514 1520 10.1093/cid/ciw173 PMC4885651 27045126